Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2018 2
2019 1
2020 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Small Cell Carcinoma"
Page 1
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C, Mahjoubi L, Gazzah A, Barlesi F. Parisi C, et al. Cancer Treat Rev. 2023 Jul;118:102572. doi: 10.1016/j.ctrv.2023.102572. Epub 2023 May 19. Cancer Treat Rev. 2023. PMID: 37230055 Review.
Promising activity of novel ADCs, namely Trastuzumab Deruxtecan and Patritumab Deruxtecan, has been observed in hard-to treat molecular subtypes, such as HER2-positive and heavily pretreated EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). However, therapeutic …
Promising activity of novel ADCs, namely Trastuzumab Deruxtecan and Patritumab Deruxtecan, has been observed in hard-to treat molecular subt …
Cannabis-based medicines and medical cannabis for adults with cancer pain.
Häuser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA. Häuser W, et al. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD014915. doi: 10.1002/14651858.CD014915.pub2. Cochrane Database Syst Rev. 2023. PMID: 37283486 Review.
There was low-certainty evidence that a synthetic THC analogue (nabilone) delivered over eight weeks was not superior to placebo in reducing pain associated with chemotherapy or radiochemotherapy in people with head and neck cancer and non-small cell lung can …
There was low-certainty evidence that a synthetic THC analogue (nabilone) delivered over eight weeks was not superior to placebo in reducing …
Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yu G, Shen Y, Xu X, Zhong F. Yu G, et al. PLoS One. 2020 Nov 30;15(11):e0242982. doi: 10.1371/journal.pone.0242982. eCollection 2020. PLoS One. 2020. PMID: 33253313 Free PMC article.
OBJECTIVE: To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell lung cancer (NSCLC). METHODS: We systematically searched databases for randomized controlled trials on anlotinib treatment for patients …
OBJECTIVE: To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell …
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.
Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Inoue M, Nakashima K, Ushio R, Shinkai M, Kudo M, Kaneko T. Horita N, et al. Sci Rep. 2015 Oct 21;5:15437. doi: 10.1038/srep15437. Sci Rep. 2015. PMID: 26486755 Free PMC article.
Topotecan is the most reliable chemotherapy regimen for relapsed small-cell lung carcinoma (SCLC). The efficacy and adverse effects of topotecan as reported by previous studies varied greatly. ...In conclusion, Topotecan provided a possibly promising o …
Topotecan is the most reliable chemotherapy regimen for relapsed small-cell lung carcinoma (SCLC). The efficacy …
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V. Khunger M, et al. Clin Lung Cancer. 2018 May;19(3):e335-e348. doi: 10.1016/j.cllc.2018.01.002. Epub 2018 Jan 10. Clin Lung Cancer. 2018. PMID: 29433902
INTRODUCTION: Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small-cell lung carcinoma (NSCLC). However, there is a relative lack of data on comparative efficacy of these drugs in the fi …
INTRODUCTION: Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small- …
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N. Goldkuhle M, et al. Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2. Cochrane Database Syst Rev. 2018. PMID: 30001476 Free PMC article. Review.
Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. ...Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration …
Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advan …
Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J. Murdoch D, et al. Curr Opin Oncol. 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. Curr Opin Oncol. 2008. PMID: 18043264 Review.
(c) Colorectal cancer (CRC) - An overview of three RCTs in metastatic CRC revealed that bevacizumab plus 5-fluorouracil/leucovorin possesses a significant survival advantage over 5-fluorouracil/leucovorin and irinotecan/5-fluorouracil/leucovorin.(d) Non-small-cell …
(c) Colorectal cancer (CRC) - An overview of three RCTs in metastatic CRC revealed that bevacizumab plus 5-fluorouracil/leucovorin possesses …
Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
Imakita T, Matsumoto H, Hirano K, Morisawa T, Sakurai A, Kataoka Y. Imakita T, et al. BMC Cancer. 2019 Jan 25;19(1):105. doi: 10.1186/s12885-019-5309-x. BMC Cancer. 2019. PMID: 30683066 Free PMC article.
This systematic review aimed to clarify whether rebiopsy contributes to improved prognosis in the first- or second-generation EGFR-TKI refractory patients. METHODS: Using free word and control terms related to "non-small cell lung cancer" and "rebiopsy …
This systematic review aimed to clarify whether rebiopsy contributes to improved prognosis in the first- or second-generation EGFR-TKI re …